neuropathic pain
Pain · 2011–2022
6decisions
1medicine
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 3 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pregabalin Treatment of neuropathic pain in adults. The condition must be refractory to treatment with other drugs. | May 2022 | Not recommended | unclear |
| pregabalin Treatment of neuropathic pain in adults. The submission also noted TGA registration for adjunctive therapy in adults with partial seizures, but the PBAC… | Nov 2021 | Deferred | none received |
| pregabalin Treatment of neuropathic pain in adults; controlled release formulation. | Nov 2021 | Deferred | unclear |
| Pregabalin Initiation and up-titration of treatment for neuropathic pain (75 mg); Initiation of treatment for neuropathic pain in patients requiring a reduced dose due to… | Mar 2012 | Recommended with restriction | no section in document |
| pregabalin Treatment of neuropathic pain in adults, including diabetic peripheral neuropathy, postherpetic neuralgia, and other neuropathic pain conditions. | Mar 2012 | Recommended with restriction | no section in document |
| pregabalin initial and continuation treatment of neuropathic pain in patients who meet certain criteria | Mar 2011 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.